Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 8, 2013, Pages 1685-1690

  Gilca, Vladimir ^a   De Serres, Gaston ^a   Boulianne, Nicole ^a   Murphy, Donald ^b   Ouakki, Manale ^a   De Wals, Phillipe ^a   Trudeau, Gisele ^c   Massé, Richard ^c   Dionne, Marc ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Canada)

^c Gouvernement du Quebec   (Canada)

Author keywords

Hepatitis B; Immunity; Long term; Persistence; Vaccination

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

HEPATITIS B; IMMUNITY; LONG TERM; PERSISTENCE; VACCINATION;

CHILD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; MALE; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 84882948636     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25015     Document Type: Article

References (27)

1. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2012.
2. Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, Zhang M. Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011; 29:2302-7; PMID:21277403; http://dx.doi.org/ 10.1016/j.vaccine.2011.01.025
3. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, et al.; Study Group. Longterm immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84; PMID:16226616; http://dx.doi.org/10.1016/S0140-6736(05)67568-X
4. Gabbuti A, Romanò L, Blanc P, Meacci F, Amendola A, Mele A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25:3129-32; PMID:17291637; http://dx.doi.org/10.1016/j.vaccine.2007.01.045
5. Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 2013; 31:448-51; PMID:23206974; http://dx.doi.org/10.1016/j.vaccine.2012.11.037
6. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004; 22:607-10; PMID:14741151; http://dx.doi.org/10.1016/j.vac-cine.2003.09.001
7. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams I T, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-5; PMID:18756185; http://dx.doi.org/10.1097/INF.0b013e31817702ba
8. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu T Y, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51:1547-54; PMID:20209603; http://dx.doi.org/10.1002/hep.23543
9. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64; PMID:17714836; http://dx.doi.org/10.1016/j.vaccine.2007.06.059
10. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004; 23:650-5; PMID:15247604; http://dx.doi.org/10.1097/01. inf.0000130952.96259.fd
11. Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV. Determinants of Long Term Protection after Hepatitis B Vaccination in Infancy: A Meta-Analysis. Pediatr Infect Dis J 2013; 32:307-13; PMID:23249904
12. Duval B, Boulianne N, De Serres G, Laflamme N, De Wals P, Massé R, et al. Comparative immuno-genicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 2000; 18:1467-72; PMID:10618544; http://dx.doi.org/10.1016/S0264-410X(99)00422-3
13. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One 2007; 2:e753; PMID:17710152; http://dx.doi.org/10.1371/journal. pone.0000753
14. Aypak C, Yüce A, Yikilkan H, Görpelioǧlu S. Persistence of protection of hepatitis B vaccine and response to booster immunization in 2-to 12-year-old children. Eur J Pediatr 2012; 171:1761-6; PMID:22895894; http://dx.doi.org/10.1007/s00431-012-1815-4
15. Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van Damme P. Immune Memory and Immune Response in Children from Bulgaria 5-15 Years after Primary Hepatitis B Vaccination. Pediatr Infect Dis J 2013; 32:51-3; PMID:22914584
16. Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, et al.; study group. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010; 10:755-61; PMID:20884297; http://dx.doi.org/10.1016/S1473-3099(10)70195-X
17. Chaves SS, Fischer G, Groeger J, Patel PR, Thompson ND, Teshale EH, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30:1644-9; PMID:22245310; http://dx.doi.org/10.1016/j. vaccine.2011.12.106
18. Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008; 198:1776-82; PMID:18976095; http://dx.doi.org/10.1086/593335
19. Spradling PR, Xing J, Williams R, et al. Immunity to hepatitis B virus infection two decades after implementation of universal infant hepatitis B vaccination: the association of detectable residual antibody and response to a single hepatitis B vaccine challenge dose. Clin Vaccine Immunol 2013; 13
20. De Serres G, Gilca V, Boulianne N, Sauvageau C, De Wals P. Hepatitis B vaccine: what is the best protection and the most relevant age? Another view of timing. Can Ass Med J 2009; 180:196-202
21. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 2000; 19:1026-37; PMID:11137236; http://dx.doi.org/10.1016/S0264-410X(00)00239-5
22. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-26; PMID:18444799; http://dx.doi.org/10.1086/587695
23. Chlibek R, von Sonnenburg F, Van Damme P, Smetana J, Tichy P, Gunapalaiah B, et al. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. J Travel Med 2011; 18:145-8; PMID:21366801; http://dx.doi.org/10.1111/j.1708-8305.2010.00499. x
24. Carollo M, Palazzo R, Bianco M, Pandolfi E, Chionne P, Fedele G, et al. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 2013; 31:506-13; PMID:23174200; http://dx.doi.org/10.1016/j.vaccine.2012.11.029
25. Dobson S, Dawar M, Money D, et al. Two dose vaccine trial of Q-HPV: results at 36 months. Oral presention. 27th International Papillomavirus Conference and Clinical Workshop, Berlin, Germany, September 17-22, 2011.
26. Duval B, Gîlca V, Boulianne N, De Wals P, Massé R, Trudeau G, et al. Comparative long term immunoge-nicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24:213-8; PMID:15750456; http://dx.doi.org/10.1097/01. inf.0000154329.00361.39
27. European, Consensus, Group. Are booster immunisations needed for lifelong hepatitis B immunity European? Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561-5; PMID:10683019; http://dx.doi.org/10.1016/S0140-6736(99)07239-6